ArticleThe Journal of pediatrics2015
Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.
Article in The Journal of pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320).Journal of perinatology : official journal of the California Perinatal Association · 2019Trial
- Article
- Racial disparities in the development of comorbid conditions after preterm birth: A narrative review.Seminars in perinatology · 2022Review
- Patent Ductus Arteriosus of the Preterm Infant.Pediatrics · 2020Review
- Molecular and Mechanical Mechanisms Regulating Ductus Arteriosus Closure in Preterm Infants.Frontiers in pediatrics · 2020Review
- Understanding the pathobiology in patent ductus arteriosus in prematurity-beyond prostaglandins and oxygen.Pediatric research · 2019Review
- Effects of antenatal betamethasone on preterm human and mouse ductus arteriosus: comparison with baboon data.Pediatric research · 2018Article
- Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.Seminars in fetal & neonatal medicine · 2018Review
- Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing.Seminars in perinatology · 2018Review
- Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.Seminars in perinatology · 2018Review
- Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.Pediatric cardiology · 2018Review
- Identification of differentially regulated genes in human patent ductus arteriosus.Experimental biology and medicine (Maywood, N.J.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo identify genes affected by advancing gestation and racial/ethnic origin in human ductus arteriosus (DA). STUDY
designWe collected 3 sets of DA tissue (n = 93, n = 89, n = 91; total = 273 fetuses) from second trimester pregnancies. We examined four genes, with DNA polymorphisms that distribute along racial lines, to identify "Caucasian" and "non-Caucasian" DA. We used real time polymerase chain reaction to measure RNA expression of 48 candidate genes involved in functional closure of the DA, and used multivariable regression analyses to examine the relationships between advancing gestation, "non-Caucasian" race, and gene expression.
resultsMature gestation and non-Caucasian race are significant predictors for identifying infants who will close their patent DA when treated with indomethacin. Advancing gestation consistently altered gene expression in pathways involved with oxygen-induced constriction (eg, calcium-channels, potassium-channels, and endothelin signaling), contractile protein maturation, tissue remodeling, and prostaglandin and nitric oxide signaling in all 3 tissue sets. None of the pathways involved with oxygen-induced constriction appeared to be altered in "non-Caucasian" DA. Two genes, SLCO2A1 and NOS3, (involved with prostaglandin reuptake/metabolism and nitric oxide production, respectively) were consistently decreased in "non-Caucasian" DA.
conclusionsProstaglandins and nitric oxide are the most important vasodilators opposing DA closure. Indomethacin inhibits prostaglandin production, but not nitric oxide production. Because decreased SLCO2A1 and NOS3 expression can lead to increased prostaglandin and decreased nitric oxide concentrations, we speculate that prostaglandin-mediated vasodilation may play a more dominant role in maintaining the "non-Caucasian" patent DA, making it more likely to close when inhibited by indomethacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.